The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 11 of those trials with a site in Rheumatoid arthritis.
11 of the 2,500 most recently authorised trials in this register list a site in Rheumatoid arthritis; 0 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
| Phase | Trials | Share |
|---|---|---|
| Phase I | 4 | 36.4% |
| Phase II | 4 | 36.4% |
| Phase IV | 3 | 27.3% |
| Lead sponsor | Trials |
|---|---|
| AbbVie Deutschland GmbH & Co. KG | 2 |
| Aalborg University Hospital, Aalborg University Hospital | 1 |
| AstraZeneca AB | 1 |
| Centre Hospitalier Universitaire De Nice | 1 |
| Elevara Medicines Limited | 1 |
| Jade Biosciences Inc. | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Neurocrine Biosciences Inc. | 1 |
| SciRhom GmbH | 1 |
| Sint Maartenskliniek Stichting | 1 |